JP2012507535A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507535A5
JP2012507535A5 JP2011534624A JP2011534624A JP2012507535A5 JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5 JP 2011534624 A JP2011534624 A JP 2011534624A JP 2011534624 A JP2011534624 A JP 2011534624A JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
hydrogen
fluoro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/061573 external-priority patent/WO2010062507A1/en
Publication of JP2012507535A publication Critical patent/JP2012507535A/ja
Publication of JP2012507535A5 publication Critical patent/JP2012507535A5/ja
Pending legal-status Critical Current

Links

JP2011534624A 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト Pending JP2012507535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
US61/110,703 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
JP2012507535A JP2012507535A (ja) 2012-03-29
JP2012507535A5 true JP2012507535A5 (OSRAM) 2012-12-13

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534624A Pending JP2012507535A (ja) 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (29)

Country Link
US (1) US8404687B2 (OSRAM)
EP (1) EP2364185B1 (OSRAM)
JP (1) JP2012507535A (OSRAM)
KR (1) KR101335746B1 (OSRAM)
CN (1) CN102202737B (OSRAM)
AU (1) AU2009320251C1 (OSRAM)
BR (1) BRPI0921437A2 (OSRAM)
CA (1) CA2742539C (OSRAM)
CL (1) CL2011000979A1 (OSRAM)
CO (1) CO6382123A2 (OSRAM)
CR (1) CR20110202A (OSRAM)
CY (1) CY1114023T1 (OSRAM)
DK (1) DK2364185T3 (OSRAM)
EA (1) EA018931B1 (OSRAM)
EC (1) ECSP11011021A (OSRAM)
ES (1) ES2418479T3 (OSRAM)
HR (1) HRP20130527T1 (OSRAM)
IL (1) IL211841A0 (OSRAM)
MA (1) MA32726B1 (OSRAM)
MX (1) MX2011004683A (OSRAM)
NZ (1) NZ591945A (OSRAM)
PE (1) PE20110433A1 (OSRAM)
PL (1) PL2364185T3 (OSRAM)
PT (1) PT2364185E (OSRAM)
SI (1) SI2364185T1 (OSRAM)
TN (1) TN2011000166A1 (OSRAM)
UA (1) UA102115C2 (OSRAM)
WO (1) WO2010062507A1 (OSRAM)
ZA (1) ZA201102448B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579402A (en) * 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
KR20230107568A (ko) 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법
CN119907797A (zh) * 2022-09-23 2025-04-29 默沙东有限责任公司 用作nod样受体蛋白3抑制剂的酞嗪衍生物
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
CN1104430C (zh) 1996-01-15 2003-04-02 詹森药业有限公司 抑制血管生成的哒嗪胺
AU719392B2 (en) * 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO2000074706A1 (en) 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
ATE404200T1 (de) 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) * 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
EP1789390B1 (en) * 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
NZ579402A (en) * 2007-03-15 2012-03-30 Novartis Ag Organic compounds for diagnosis and treatment of pathologies relating to the Hedgehog pathway
AU2008269128B2 (en) 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
ES2392157T3 (es) 2007-09-07 2012-12-05 Amgen Inc. Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012507535A5 (OSRAM)
JP2012530705A5 (OSRAM)
JP2012509263A5 (OSRAM)
JP2011529054A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2014515013A5 (OSRAM)
JP2016503786A5 (OSRAM)
JP2011527666A5 (OSRAM)
JP2011519854A5 (OSRAM)
JP2015512931A5 (OSRAM)
JP2011528658A5 (OSRAM)
JP2012533546A5 (OSRAM)
JP2009545527A5 (OSRAM)
JP2010513478A5 (OSRAM)
JP2010533722A5 (OSRAM)
JP2009535462A5 (OSRAM)
JP2006526031A5 (OSRAM)
JP2009502743A5 (OSRAM)
JP2013523733A5 (OSRAM)
JP2011527332A5 (OSRAM)
JP2010521516A5 (OSRAM)
JP2015531774A5 (OSRAM)
JP2015501799A5 (OSRAM)
JP2008513510A5 (OSRAM)
JP2013506674A5 (OSRAM)